STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Esophagogastric Cancer Clinical Trial

Official title: A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers

Status Completed

Clinical Trial Summary

In this research study, the investigators are looking to see how effective STA-9090 is in treating esophagogastric cancer. The investigators will also evaluate the side effects of STA-9090, and examine the relationship between the presence of HSP-90 and how well study participants respond to STA-9090. STA-9090 works by blocking a protein in tumor cells called HSP90, which is thought to play a role in tumor growth. By interfering with this protein's function, STA-9090 may help kill tumor cells. This drug has been used in other research studies and information from those other research studies suggests that this agent may help to slow tumor growth in esophagogastric cancer.

Clinical Trial Description

• Each treatment cycle lasts 4 weeks during which time the study drug will be administered for three consecutive weeks followed by 1 week of no study drug. STA-9090 will be given by intravenous infusion.

• Participants will come to the clinic on Days 1, 8, and 15 of all cycles. At these visits, the following tests and procedures will be performed: Review of current medications and any side effects experienced; Performance status evaluation; Physical examination; Vital signs; Routine blood tests; CT scan of the chest, abdomen, and pelvis (every 2 cycles) and Optional FDG-PET scan (every 2 cycles).

• Participants may remain on this research study for as long as their cancer is responding to the study drug and they are not experiencing any severe side effects. ;

Related Conditions & MeSH terms

• Esophagogastric Cancer

• NCT number: NCT01167114
• Study type: Interventional
• Source: Massachusetts General Hospital
• Status: Completed
• Phase: Phase 2
• Start date: August 2010
• Completion date: April 2017